Non-Current Liabilities
Operating Lease Liabilities (Total)
Regeneron Pharmaceuticals Operating Lease Liabilities (Total) increased by 13.8% to $266.80M in Q4 2025 compared to the prior quarter. Over 2 years (FY 2023 to FY 2025), Operating Lease Liabilities (Total) shows an upward trend with a 74.4% CAGR.
Analysis
StatementBalance Sheet Statement
SectionNon-Current Liabilities
CategoryLeverage
SignalContext dependent
VolatilityModerate
First reportedQ4 2019
Last reportedQ4 2025Feb 4, 2026
How to read this metric
An increase indicates expansion of the leased asset base, while a decrease suggests a reduction in lease commitments or the expiration of lease terms.
Detailed definition
This represents the total present value of future lease payments for operating leases, recognized as a liability on the...
Peer comparison
Standardized under modern accounting rules, allowing for direct comparison of lease-based financing across companies in the same sector.
Metric ID:
operating_lease_liabilities_totalHistorical Data
3 periods
| Q4 '23 | Q4 '24 | Q4 '25 | |
|---|---|---|---|
| Value | $87.70M | $234.40M | $266.80M |
| QoQ Change | — | +167.3% | +13.8% |
| YoY Change | — | +167.3% | +13.8% |
Range$87.70M – $266.80M
Avg YoY Growth+90.5%
Median YoY Growth+90.5%
Current Streak2+ quarters growth
Operating Lease Liabilities (Total) at Other Companies
Frequently Asked Questions
- What is Regeneron Pharmaceuticals's operating lease liabilities (total)?
- Regeneron Pharmaceuticals (REGN) reported operating lease liabilities (total) of $266.80M in Q4 2025.
- What is the long-term trend for Regeneron Pharmaceuticals's operating lease liabilities (total)?
- Over 2 years (2023 to 2025), Regeneron Pharmaceuticals's operating lease liabilities (total) has grown at a 74.4% compound annual growth rate (CAGR), from $87.70M to $266.80M.
- What does operating lease liabilities (total) mean?
- The total value of future payments the company is obligated to make for leased assets.